Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2005 to 31 December 2005

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2006/C 20/02)

— Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
23.12.2005	Kinzalkomb	Bayer AG, D-51368 Leverkusen	EU/1/02/214/001-010	29.12.2005
23.12.2005	PhotoBarr	Axcan Pharma International BV, Engelenkampstraat 72, 6131 JJ Sittard, Nederland	EU/1/04/272/001-002	28.12.2005
23.12.2005	Aptivus	Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein	EU/1/05/315/001	28.12.2005
23.12.2005	Avastin	Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom	EU/1/04/300/001-002	3.1.2006
23.12.2005	Stocrin	Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/99/111/001-009	3.1.2006
23.12.2005	Zometa	Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/01/176/001-006	3.1.2006
23.12.2005	Sustiva	Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UD8 1DH, United Kingdom	EU/1/99/110/001-009	3.1.2006
23.12.2005	Rilutek	Aventis Pharma SA, 20 Avenue Raymond Aron, F-Antony Cedex 92165	EU/1/96/010/001	28.12.2005
23.12.2005	Revasc	Canyon Pharmaceuticals Ltd, 20-22 Bedford Row, WC1R 4JS London, United Kingdom	EU/1/97/043/001-003	3.1.2006
23.12.2005	Invirase	Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom	EU/1/96/026/001-002	3.1.2006
23.12.2005	Regranex	Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse	EU/1/99/101/001	2.1.2006
23.12.2005	MicardisPlus	Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein	EU/1/02/213/001-010	5.1.2006

[1] OJ L 136, 30.4.2004, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
23.12.2005	BeneFIX	Wyeth Europa Ltd, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/97/047/001-003	28.12.2005
23.12.2005	Fortovase	Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom	EU/1/98/075/001-002	3.1.2006
23.12.2005	Truvada	Gilead Sciences International Limited, Granta Park Abington Cambridge CB1 6GT, United Kingdom	EU/1/04/305/001	3.1.2006

— Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
23.12.2005	Zubrin	Schering-Plough Limited, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom	EU/2/00/028/001-008	28.12.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom